The OC3 is an international consortium of cohort studies whose mission is to address scientific aims important for understanding ovarian cancer risk, early detection, tumor heterogeneity, and prognosis. The OC3 is part of the NCI Cohort Consortium, which is an extramural-intramural partnership to address the need for large-scale collaborations and provides the super-structure (but not funding) for managing the OC3. The OC3 currently has over 20 participating, on-going cohort studies and we expect there to be over 8,000 invasive ovarian cancer cases among more than 1.5 million women. The goals of the OC3 are to bring together cohorts with ovarian cancer endpoints for pooled projects, build a focused group of ovarian cancer researchers, and develop a comprehensive approach that integrates questionnaire and pathology data with biomarkers, genetics, and tissue.
Hurwitz LM, Townsend MK, Jordan SJ, Patel AV, Teras LR, Lacey JV Jr, . . . Trabert B. Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia. J Clin Oncol. 2022. doi: 10.1200/JCO.21.01900.
Townsend MK, Trabert B, Fortner RT, Arslan AA, Buring JE, Carter BD, . . . Wentzensen N. Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3). Int J Epidemiol. 2022. doi: 10.1093/ije/dyab211.
Trabert B, Tworoger SS, O'Brien KM, Townsend MK, Fortner RT, Iversen ES, . . . Wentzensen N. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res. 2020. doi:10.1158/0008-5472.CAN-19-2850